Pliant Therapeutics' GAAP loss for 9M 2021 was $72.732 million, up 3.2 times from $22.506 million in the previous year. Revenue decreased 6.7-fold to $5.573 million from $37.352 million a year earlier.
Pliant Therapeutics' GAAP loss for 9M 2021 was $72.732 million, up 3.2 times from $22.506 million in the previous year. Revenue decreased 6.7-fold to $5.573 million from $37.352 million a year earlier. 
ir.pliantrx.com
English (US) 